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Lasse J Lapidus1*, Sari Ponzer1, Hans Pettersson2 and Edin de Bri1Abstract
Background: Little information exists on the presentation of symptomatic venous thromboembolism (VTE) in
orthopaedic surgery when a defined protocol for thromboprophylaxis is used. The objective with this study was to
establish the VTE rate and mortality rate in orthopaedic surgery.
Methods: We performed a prospective, single centre observational cohort study of 45 968 consecutive procedures
in 36 388 patients over a 10 year period. Follow-up was successful in 99.3%. The primary study outcome was the
incidence of symptomatic deep vein thrombosis (DVT), symptomatic pulmonary embolism (PE) and mortality at
6 weeks, specified for different surgical procedures. The secondary outcome was to describe the DVT distribution in
proximal and distal veins and the proportion of VTEs diagnosed after hospital discharge. For validation purposes, a
retrospective review of VTEs diagnosed 7–12 weeks postoperatively was also performed.
Results: In total, 514 VTEs were diagnosed (1.1%; 95% CI: 1.10-1.14), the majority (84%) after hospital discharge (432
out of 514).With thromboprophylaxis, high incidence of VTE was found after internal fixation (IF) of pelvic fracture
(12%; 95% CI: 5–26), knee replacement surgery (3.7%; 95% CI: 2.8-5.0), after internal fixation (IF) of proximal tibia
fracture (3.8%; 95% CI: 2.3-6.3) and after IF of ankle fracture (3.6%; 95% CI: 2.9-4.4). Without thromboprophylaxis,
high incidence of VTE was found after Achilles tendon repair (7.2%; 95% CI: 5.5-9.4). In total 1094 patients deceased
(2.4%; 95% confidence interval (CI): 2.33- 2.44) within 6 weeks of surgery. Highest mortality was seen after lower
limb amputation (16.3%, CI: 13.8-19.1) and after hip hemiarthroplasty due to hip fracture (9.6%, CI; 7.6-12.1).
Conclusion: The overall incidence of VTE is low after orthopaedic surgery but our study highlights surgical
procedures after which the risk for VTE remains high and improved thromboprophylaxis is needed.
Keywords: Deep vein thrombosis, Mortality, Operation, Orthopaedic surgery, Prophylaxis, Pulmonary embolism,
Thrombosis, Venous thromboembolismBackground
Orthopaedic surgery is a well-known risk factor for
venous thromboembolism (VTE), associated with short
term mortality and long term morbidity [1]. The use of
thromboprophylaxis is uncontroversial in high risk situa-
tions such as major joint surgery in hips and knees but
less well defined, and sometimes questioned, for many
other non-major orthopaedic procedures [2]. While a
large number of reports have found a high incidence of* Correspondence: lasse.lapidus@sodersjukhuset.se
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reproduction in any medium, provided the orVTE in screening studies, mostly asymptomatic, little
information exists on the clinical presentation and the
time-course of postoperative symptomatic VTE when a
defined protocol for thromboprophylaxis has been used,
particularly after lower limb fractures. Studies presenting
the outcome of such protocols are particularly important
when the daily clinical practice offers limited possibilities
of postoperative VTE surveillance over the time at risk,
leaving the VTE outcome of the patients unknown for
the treating surgeon. The late occurrence of postopera-
tive VTEs [3-5] and the widespread tradition with in-
ternist diagnosing and treating VTEs could also reducel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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orthopaedic surgeons.
This prospective study was performed in order to
present the VTE outcome of a defined protocol for
thromboprophylaxis and update the epidemiological data
on VTE complications and mortality following a wide
range of different orthopaedic procedures in large cohort
of consecutive patients. The results represent all symp-
tomatic events of VTE diagnosed within 6 weeks of
surgery. Diagnostic investigations where performed only
when the clinical suspicion of VTE was high.
Methods
This prospective single center study was conducted at
the Department of Orthopedics at Södersjukhuset Hos-
pital in Stockholm between 1996 and 2005. The hospital
is a public general hospital with a catchment area com-
prising about 600,000 inhabitants. All patients from the
age of 15 operated at the department were included in
the study, only patients participating in clinical trials in-





(n = 45968) (25th–75th percentile
Hip replacement 4001 77.2 (68–84)
(all indications)
Knee replacement 1309 72.4 (64–78)
(all indications)
Spine surgery 1320 50.4 (38–67)
(all indications)
Lower Limb Amputation 923 81.5 (74–87)
Pelvic and lower limb fractures 12739 78.7 (60–86)




Knee arthroscopy 6057 38.6 (29–51)
Achilles tendon rupture 764 39.8 (33–48)
Foot surgery 2373 52.8 (39–65)
Upper extremity surgery 8695 55.0 (39–71)
Miscellaneous procedures
in the lower limb
1322 51.3 (34–71)
Minor surgery 5806 59.9 (41–77)
IF Internal fixation.
* Only the most frequent anaesthetic method is specified.
† Postoperative start with dalteparin 5000 U given subcutaneously once daily starti
For fracture patients’ preoperative thromboprophylaxis was used as follows;
Until March 31, 2000: dalteparin 5000 U subcutaneously at admission.
From April 1, 2000: 1000 mL RingerDextran60® intravenously at admission.
‡ Graduated compression stockings were used as a postoperative complement to L
§ Prophylaxis based on surgeons preference. In general, prophylaxis was given afte
given after soft tissue surgery.for thromboprophylaxis was established at the depart-
ment before study start, two minor changes were
performed during the study period (Table 1). All patients
operated at the department were assigned to a six week
follow-up within the context of a clinical audit based on
a questionnaire distributed to the patients in a prepaid
envelope before discharge. In this questionnaire the pa-
tients were encouraged to report any adverse event after
surgery and where this had been diagnosed and treated.
One research nurse was responsible for the data collec-
tion (one and the same during the entire study period).
In cases when the questionnaire was not returned (in
approximately 50% of the cases), one or more reminders
were sent to the patient. If necessary, contact with rela-
tives or carers was established to ensure the follow-up.
Medical records were requested for all (100%) adverse
events reported in the questionnaires, also from care in-
stitutions elsewhere. An orthopaedic surgeon (5 different
surgeons during the study period) reviewed the medical
records in case of reported adverse event. All VTEs con-
firmed in medical records (patients diagnosed with andboprophylaxis regimen in relation to the surgical
Female gender Type of
anaesthesia*
Thromboprophylaxis †
) - n (%)
2794 (69.8) >90% spinal Yes ‡
854 (65.2) >90% spinal Yes ‡
677 (51.3) >90% general Yes
491 (53.2) 80-90% spinal Yes
8489 (66.6) 85-90% spinal Yes
240 (36.4) 80-90% general Yes
2469 (40.8) 70-80% general No
131 (17.1) 70% local No
1508 (63.5) 40% local No
5061 (58.2) 70% general No
608 (46.0) 50% spinal Individual §
3073 (52.9) 50% general No
ng on the evening after surgery and continuing for 7 to 10 days.
MWH until 9th of February 2000.
r major procedures in bone (such as osteotomies) while no prophylaxis was
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gery were considered to be related to the surgery and
thus included in the analysis. DVT was defined as any
thrombosis diagnosed by venography or duplex sonog-
raphy (CDS) and they were classified to be either distal
(below the popliteal vein), proximal (in or above the
popliteal vein) or located in the upper extremity. PE was
diagnosed by computer tomography (CT), pulmonary
angiography, ventilation-perfusion scintigraphy, or at
autopsy. The images were reviewed in the clinical setting
at the time of examination, not adjudicated separately in
the study.
All data concerning adverse events and surgical proce-
dures were continuously collected and stored in a local
database which was based on the unique Swedish
personal identification number. A validation of the data
base was performed in two retrospective analyses in
order to verify correct registration of surgical procedures
and VTE events within 6 weeks. For validation purposes,
we also performed a retrospective review of VTE events
diagnosed at the hospital 7–12 weeks after surgery
(details are presented in the results section).
The primary study outcome was the incidence of
symptomatic DVT and PE within six weeks of surgery.
The secondary outcome was the distribution of DVTs in
proximal and distal veins and the proportion of VTEs
diagnosed after discharge from the hospital and the all-
cause mortality at 6 weeks. The impact of two minor
changes in the VTE prophylaxis protocol was evaluated
(i.e. the VTE incidence after hip and knee replacement
surgery was calculated with and without the use of
postoperative compression stockings (used as a comple-
ment to LMWH until January 31st 2001) and the VTE
incidence after internal fixation (IF) of lower extrem-
ity fractures (excluding foot fractures) was calculated
before and after the change of preoperative prophy-
laxis from dalteparin to Ringer-Dextran60® (dextran
60) (April 1, 2000)).
The study was assessed by the Regional Ethics Com-
mittee in Stockholm (reference no. 296/03) but since
this survey did not impact on the daily clinical practice,
no formal approval was requested. However, the study
was conducted according to ethical principles stated in
the Declaration of Helsinki.
Statistical analysis
Patient demographics were calculated as median age
(with 25 and 75 percentile) because the age distribution
was skewed at the time of the surgery (at their first sur-
gical procedure if included more than once in the study).
VTE incidence and mortality are presented with 95%
confidence intervals (CI) using the Poisson distribution.
Patients with more than one surgical procedure during a
90 day period were only included once in the analysis(the procedure with longest operating time was calcu-
lated). In the final analysis of VTEs, all events were
counted until postoperative day 42, including DVTs and
PEs primarily missed in the registration but detected in
the validation process. The time to DVT or PE diagnosis
is presented as the median number of days after surgery,
differences were tested using Mann Whitney U test since
censoring due to lot to follow-up was not a problem
within the first 42 days. The impact of the changes in
the VTE prophylaxis protocol was tested by the Fisher’s
exact test. A p-value less than 0.05, two-tailed, were
regarded as significant.
The statistical software used was IBM SPSS Statistics,
Version 20 for Windows (IBM, New York, USA).Results
Validation of surgical procedures and VTEs
The accuracy of the surgical procedure codes in our
register was compared against the patient medical rec-
ord database (Pasett®) for all cases coded as “IF of femur
fracture” (NFJ) in the Swedish version of NCSP 96
(Nomesco Classification of Surgical Procedures) between
the years 1999 and 2003 (n = 4586). All discrepancies
were checked manually in patients’ records. There was a
99.9% (4578/4586) agreement in this coding between the
different databases. One incorrect code was found in our
register compared to seven incorrect codes in the refer-
ence database Pasett® (ie: IF when a hip prosthesis in fact
had been performed).
To validate the completeness of our VTE registrations,
we used Pasett® and identified all patients diagnosed with
VTE at the hospital (1998–2005) and compared the find-
ings with our database. In this analysis we found 14 more
patients that had been treated for VTE (11 for DVT and 3
for PE) within 6 week after surgery. For one patient with a
registered PE, the PE diagnosis had been re-evaluated and
withdrawn at the treating department although this had
not passed through to our register. Corrections were sub-
sequently performed in the register before analysis.
To validate the methodology, using a 6 week monitoring
of postoperative VTE, we used Pasett® and identified all
patients diagnosed with VTE at the hospital 7 to 12 weeks
after surgery. In this analysis we found another 37 DVTs
(7 after proximal femoral fracture, 7 after hip replacement,
5 after knee replacement, 5 after Achilles tendon repair, 3
after ankle fracture, 3 after other lower extremity surgery,
2 after femur fracture, 2 after upper extremity surgery, 1
after foot surgery, 1 after minor surgery and 1 after lower
limb amputation) and 9 PEs ( 5 after proximal femoral
fracture, 1 after hip replacement, 1 after knee replacement,
1 after foot surgery and 1 after knee arthroscopy). These
late VTEs represented 10% (46/473) of postoperative
VTEs during the years 1998–2005.
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A total of 46 796 surgical procedures were performed
during the study period and enrolled in our clinical audit
database, 530 procedures were excluded from the ana-
lysis (93 procedures on infants and 427 procedures on
patients participating in clinical trials involving throm-
bosis screening) and 308 cases (0.7%) were lost to
follow-up leaving 45 968 procedures in 36 388 patients
to be included in the analysis, 56.6% of patients being
female (20 590). The median age was 71.1 years (25 and
75 percentile: 51–83 years) for women and 50.4 years
(25 and 75 percentile: 34–70 years) for men. The median
age for patients diagnosed with a VTE was 74.2 years (25
and 75 percentile: 56–83 years) for women and 54.5 years
(25 and 75 percentile: 37–70 years) for men. Median age
and gender distribution in relation to different surgical
procedures is presented in Table 1, 2 and 3.
Surgical characteristics
Surgical procedures, thromboprophylaxis and anaesthetic
method are presented in Table 1. The indication for hip
prosthesis surgery is specified separately in Table 2 and
the different lower extremity fractures are presented in de-
tail in Table 3.
The indication for knee replacement surgery was osteo-
arthritis or rheumatoid arthritis (n = 1226), knee revision
surgery (n = 81) and fracture (n = 2). Spinal surgery was
performed due to degenerative spine disorders (n = 1135),
fracture (n = 95), malignancy (n = 70) or infection (n = 20).
Amputation of the lower limb was performed due to
compromised circulation or infection in 912 cases and
due to trauma in 11 cases. The amputation level was
trans-tibial (n = 546), a disarticulation of the knee (n =
244), trans-femoral (n = 127), a disarticulation of the hip
(n = 5) and a disarticulation of the talo-crural joint in oneTable 2 Age, gender, VTE incidence and all-cause mortality fo
surgery










-Degenerative hip disorder 1691 71.1 (62–78) 1101 (65.1
-Fracture 348 78.5 (73–83) 272 (78.2)
- Fracture sequelae 522 77.9 (70–84) 392 (75.1)
Hemiarthroplasty
- hip fracture 743 84.9 (80–89) 565 (76.0)
- Fracture sequelae 239 84.9 (81–90) 192 (80.3)
Hip prosthesis revision 429 74.8 (64–82) 251 (58.5)
Hip replacement - malignancy 29 64.3 (58–78) 21 (72.4)
Thromboprophylaxis was used for 7 to 10 days.
Fracture sequelae = osteonecrosis of the femoral head or non-union and or implantcase. Miscellaneous procedures in the lower extremity in-
clude different skeletal and soft tissue procedures (such as
different correction osteotomies, patella tendon repairs
and quadriceps tendon repairs). Minor surgical procedures
represent mostly wound debridements, closed reductions
of joint dislocations and other related procedures.
Characteristics of VTEs
In total, 401 DVTs (0.9%) and 123 PEs (0.3%) were diag-
nosed during the study period. In ten patients DVT and
PE were diagnosed simultaneously. A proximal DVT was
found in 133 (33%) cases, a distal DVT in 241 (60%) cases
and an arm thrombosis was found in 2 cases (including
one patient with fatal PE). In 25 cases (6%) the distribution
of the lower extremity DVT was not specified.
The median time for DVT diagnosis for all patients was
16 days (range 0–42) after surgery and 342 out of 401
(85%) DVTs were diagnosed after hospital discharge.
The median time for DVT diagnosis differed significantly
(p = < 0.001) after hip replacement (26 days, range 0–42)
compared to knee replacements (6 days, range 0–42).
Consequently the majority (92%) of DVTs after hip re-
placement was diagnosed after hospital discharge (49 out
of 53) compared to 45% (26 out of 47) after knee replace-
ments. The distribution of DVTs in distal and proximal
veins is presented in Table 4. For fracture patients treated
with IF the share of proximal DVT was 53% (n = 31) for
pelvis and femur fractures combined, 20% (n = 5) for tibia
fractures and 16% (n = 12) for ankle fractures.
In total, 38 out of 123 PEs were fatal (31%), 20 of these
were diagnosed at autopsy and the other 18 were
diagnosed with CT or ventilation-perfusion scintigraphy
before death.
Fatal events of PE occurred after IF of femur fracture
(n = 18), lower limb amputation (n = 5), minor proceduresllowing hip arthroplasty in relation to indication for
Mortality – n
(%)






) 10 (0.6; 0.3-1.1) 40 (2.4; 1.7-3.2) 14 (0.8; 0.5-1.4) 28 (1.7; 1.1-2.4)
9 (2.6; 1.3-5.0) 10 (2.9; 1.5-5.3) 3 (0.9; 0.3-2.7) 7 (2.0; 1.0-4.2)
13 (2.5; 1.4-4.3) 14 (2.7; 1.6-4.5) 6 (1.2; 0.5-2.6) 8 (1.5; 0.8-3.1)
71 (9.6; 7.6-12.1) 7 (0.9; 0.4-2.0) 6 (0.8; 0.4-1.8) 1 (0.1; 0.02-1.0)
15 (6.3; 3.8-10.4) 3 (1.3; 0.4-3.9) 0 3 (1.3; 0.4-3.9)
3 (0.7; 0.2-2.2) 5 (1.2; 0.5-2.8) 0 5 (1.2; 0.5-2.8)
1 (3.4; 0.5-24.5) 1 (3.4; 0.5-24.5) 0 1 (3.4; 0.5-24.5)
failure after hip fracture surgery.
Table 3 Age, gender, VTE incidence and all-cause mortality following internal fixation (IF) of lower extremity fracture






gender – n (%)
Mortality – n
(%; 95% CI)






Pelvis 52 46 (33–57) 21 (40) 1 (2; 0–14) 6 (12; 5–26) 3 (6; 2–18) 3 (6; 2–18)
Proximal femur 8402 83.3 (77–88) 6129 (72.9) 617 (7.3; 6.8-7.9) 96 (1.1; 0.9-1.4) 39 (0.5; 0.3-0.6) 57 (0.7; 0.5-0.9)
Femur, other 581 78.4 (62–86) 433 (74.5) 27 (4.6; 3.2-6.8) 12 (2.1; 1.2-3.6) 2 (0.3; 0.1-1.4) 10 (1.7; 0.9-3.2)
Patella 169 62.3 (45–74) 95 (56.2) 0 0 0 0
Tibia, proximal 395 52.6 (39–66) 208 (52.7) 2 (0.5; 0.1-2.0) 15 (3.8; 2.3-6.3) 3 (0.8; 0.2-2.4) 13 (3.3; 1.9-5.7)
Tibia, diaphysis 502 46.6 (33–58) 194 (38.6) 3 (0.6; 0.2-1.9) 11 (2.2; 1.2-4.0) 3 (0.6; 0.2-1.9) 8 (1.6; 0.8-3.2)
Tibia, distal 175 47.6 (37–61) 77 (44.0) 0 3 (1.7; 0.6-5.3) 2 (1.1; 0.3-4.6) 1 (0.6; 0.1-4.1)
Ankle 2463 51.3 (37–62) 1332 (54.1) 5 (0.2; 0.1-0.5) 89 (3.6; 2.9-4.4) 11 (0.4; 0.2-0.8) 78 (3.2; 2.5-4.0)
Thromboprophylaxis was used for 7 to 10 days.
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(n = 1), spine surgery (n = 1), upper extremity surgery
(n = 1) and hip replacement (n = 10, distributed to follow-
ing indications: fracture (n = 4), fracture sequele (n = 3)
and degenerative hip disorder (n = 3)).
The median time to PE diagnosis was 23 days (range
0–42) and 99 out of 123 (80%) of PEs were diagnosed
after hospital discharge.Table 4 VTE incidence and all-cause mortality in relation to th
Mortality All VTE P
(n = 1094) – n
(%)




Hip replacement* 122 (3.0; 2.6-3.6) 80 (2.0; 1.6-2.5) 2
(all indications)
Knee replacement* 1 (0.1; 0.01-0.5) 49 (3.7; 2.8-5.0) 3
(all indications)
Spine surgery (all indications)* 8 (0.6; 0.3-1.2) 4 (0.3; 0.1-0.8) 3
Lower Limb Amputation* 150 (16.3; 13.8-19.1) 8 (0.9; 0.4-1.7) 7
Pelvic and lower limb
fractures - IF
655 (5.1; 4.8-5.6) 232 (1.8; 1.6-2.1) 6
(excl. foot fractures)
Knee arthroscopy 4 (0.1; 0.02-0.2) 28 (0.5; 0.3-0.7) 3
Anterior Cruciate Ligament
reconstruction*
0 3 (0.5; 0.1-1.4) 0
Achilles tendon ruptures 0 55 (7.2; 5.5-9.4) 0
Foot surgery 1 (0.04; <0.01-0.3) 16 (0.7; 0.4-1.1) 1
Upper extremity surgery 34 (0.4; 0.3-0.5) 15 (0.2; 0.1-0.3) 8
Miscellaneous procedures
in the lower limb
26 (2.0; 1.3-2.9) 19 (1.4; 0.9-2.2) 4
Minor surgery 93 (1.6; 1.3-2.0) 5 (0.1; 0.04-0.2) 2
IF Internal fixation.
* Thromboprophylaxis given according to protocol.
† Based on 374 DVTs with defined distribution of the DVTs.
‡ Rate of proximal DVT was 53% (n = 31) for pelvis and femur fractures, 20% (n = 5)
§ Rate of post-discharge VTE was 85% (n = 97) for pelvis and femur fractures, 72% (VTE incidence in relation to different surgical procedures
The VTE incidence after different surgical procedures is
presented in Tables 4, 2, 3. In Table 2 the VTE incidence
after hip replacement is presented in relation to the in-
dication for surgery and in Table 3 the VTE incidence
after IF of lower limb fractures is presented. Some
results are noteworthy. With the use of thrombo-
prophylaxis, the highest incidence of VTE was founde surgical procedure





VTE – n (%)
n = 123)– n
%; 95% CI)
(n = 399) – n
(%; 95% CI)
9 (0.7; 0.5-1.0) 53 (1.3; 1.0-1.7) 33 (70) 72 (90)
(0.2; 0.1-0.7) 47 (3.6; 2.7-4.8) 14 (30) 25 (57)
(0.2; 0.1-0.7) 1 (0.1; 0.01-0.5) 1 (100) 3 (75)
(0.8; 0.4-1.6) 2 (0.2; 0.05-0.9) 0 3 (38)
3 (0.5; 0.4-0.6) 170 (1.3; 1.1-1.6) 48 (31)‡ 199 (86) §
(0.05; 0.02-0.2) 28 (0.5; 0.3-0.7) 14 (52) 24 (83)
3 (0.5; 0.1-1.4) 1 (33) 3 (100)
55 (7.2; 5.5-9.4) 8 (15) 55 (100)
(0.04; <0.01-0.3) 15 (0.6; 0.4-1.0) 0 15 (94)
(0.1; 0.05-0.2) 7 (0.1; 0.04-0.2) 5 (83) 12 (86)
(0.3; 0.1-0.8) 17 (1.3; 0.8-2.1) 8 (47) 15 (79)
(0.03; 0.01-0.1) 3 (0.1; 0.02-0.2) 1 (33) 3 (60)
for tibia fractures and 16% (n = 12) for ankle fractures.
n = 21) for tibia fractures and 91% (n = 81) for ankle fractures.
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replacement surgery (3.7%; 95% CI: 2.8-5.0), after IF of
proximal tibia fractures (3.8%; 95% CI: 2.3-6.3) and after
IF of ankle fractures (3.6%; 95% CI: 2.9-4.4).
Without thromboprophylaxis, the highest incidence of
VTE was found after repair of Achilles tendon ruptures
(7.2%; 95% CI: 5.5-9.4).
No significant difference (p = 0.6) in VTE incidence
was found when changing the preoperative thrombo-
prophylaxis for lower extremity fracture patients (13 830
patients included in the analysis) from dalteparin to
RingerDextran60® (1.7% and 1.9%, respectively). Nor did
we find any significant difference in VTE incidence after
hip and knee replacement surgery in 5310 patients when
we stopped using postoperative compression stockings,
the VTE incidence was 2.7% before and 2.3% after the
change (p = 0.4).
All-cause mortality
The overall mortality at 6 weeks was 2.4% (n = 1094)
with a median of 14 days (SD 12) to death. Autopsy was
performed in 45 (4%) cases. In 20 out of 45 cases a PE
was found to have either contributed to death or to have
been the major cause of death (as described by the
pathologist). The mortality in the different groups is
presented in Tables 4, 2, 3. The highest 6 week mortality
was seen after lower limb amputation (16.3%; 95% CI:
13.8-19.1), after hip hemiarthroplasty due to hip fracture
(9.6%; 95% CI: 7.6-12.1) and after IF of proximal femoral
factures (7.3%; 95% CI: 6.8-7.9). These patients also had
the highest median ages in the study population;
82 years, 85 years and 83 years, respectively.
The 6 week mortality after hip fracture surgery (IF and
hip replacement combined) was 1.8% (2/110) in patients
with a confirmed diagnosis of DVT and 6.0% (737/
12289) in patients without a DVT diagnosis (p = 0.07).
Discussion
The present prospective observational study provides a
comprehensive analysis of the epidemiology of VTE after
orthopaedic surgery in patients enrolled in a well-defined
protocol for thromboprophylaxis. We demonstrate how
mortality and the outcome of VTE events differs between
procedures, that the proportion of VTEs diagnosed after
discharge from the hospital is correlated to the type of
surgery as well as the distribution of DVTs in proximal
and distal veins. We also show that no additional protec-
tion against VTE was found by using compression stock-
ings after major hip and knee surgery.
Previous epidemiological studies in elective hip and
knee replacement surgery have shown rates of symptom-
atic VTE between 1.1 and 10.6% [6-10]. Our results is
similar to these, with a VTE rate of 2.4% (95% CI: 1.7-3.2)
after hip replacement (degenerative hip disorder) and3.7% (95% CI: 2.8-5.0) after knee replacement, but in the
higher range compared to the 1.3% after hip replacement
and 2.8% after knee replacement in the FOTO-study [11],
particularly when considering the shorter follow-up in our
study (42 days vs. 90 days). The difference could be
explained by the shorter duration of thromboprophylaxis
in our study (7–10 days vs. 36 days), a difference that has
a significant impact on the risk of developing postopera-
tive VTE, at least after hip replacement surgery [12-16].
Our findings, with a significantly lower rate of VTE after
hemiarthoplasty of the hip (0.9%; 95% CI: 0.4-2.0) and
(1.3%; 95% CI: 0.4-3.9) for different indications compared
to that after total hip replacement for different indications
(2.4%; 95% CI: 1.7-3.2), (2.7%; CI: 1.6-4.5), (2.9%; 95% CI:
1.5-5.3) is surprising and could represent a positive effect
of less traumatizing surgery in hemiarthroplasties. How-
ever, it is more likely that VTEs in these more elderly pa-
tients in a higher degree remains undiagnosed and
possibly more often result in sudden death rather than in
the diagnosis of a VTE, reflected by the high mortality.
This could be supported by the fact that PEs were found
more often than DVTs after hip hemiarthroplasty and by
the trend with reduced 6 week mortality after hip surgery
(IF and hip replacement) in patients with a confirmed
VTE diagnosis compared to those without, 1.8% (2/110)
and 6.0% (737/12289), respectively (p = 0.07). Poor clinical
awareness of thromboembolic complications or a high
rate of undiagnosed fatal PEs, possibly due to asymptom-
atic DVTs, could also explain the low rate of VTE after IF
of proximal femur fractures, 1.1% (95% CI: 0.9-1.4) and
after lower limb amputations, 0.9% (95% CI: 0.4-1.7).
These results are remarkable considering that VTE is the
fourth most common cause of death, contributing to 14%
of all deaths after hip fracture surgery [17,18], and also
represent a significant risk factor for deaths after lower
limb amputation [19]. The VTE rates after IF of other
femur fractures (2.1%; 95% CI: 1.2-3.6) could be biased by
the same reason. An unacceptably high VTE incidence
despite thromboprophylaxis was found after IF of lower
limb fractures below the knee (excl. foot fractures) and
better prophylactic regimes are required in these injuries.
Proximal tibia fractures seem to be correlated with a par-
ticularly high risk for VTE compared to other tibia frac-
tures [20,21] however this difference was not significant in
our study. The rate of VTE after ankle fracture (3.6%; 95%
CI: 2.9-4.4) was significantly higher than the reported
0.4% found in one analysis of over 45 000 cases [2], a dif-
ference that could be explained by insufficient data quality
in the hospital admission database used in the later study.
In one placebo-controlled randomized trial (RCT), we
were unable to significantly reduce the risk for VTE after
ankle fracture surgery when extending the prophylaxis
with dalteparin from one to six weeks [22]. We found
similar results, with no significant risk reduction of VTE,
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repair [23]. In the present study, the DVT rate was as high
as 7.2% (CI: 5.5-9.4). The outcome of VTEs after Achilles
tendon rupture seems to be favorable however, since long
term follow-up studies have not shown any evidence of
post thrombotic syndrome (PTS), neither after asymptom-
atic DVT [24] nor after symptomatic DVT [25]. This is
probably explained by the high (85%) rate of distally
distributed DVTs found in the present study. Contrary to
our findings, significant reduction of VTE in plaster cast
immobilization of ankle fractures and soft-tissue injuries
using low molecular weight heparin (LMWH) was shown
in a more recent meta-analysis [26].
The finding of only 4 VTEs in 1320 spine procedures
in our study (0.3%, CI: 0.1-0.8) is significantly lower than
the reported rate of DVT and PE (3.7% and 2.2%, re-
spectively) in a review of lumbar fusion surgery without
thromboprophylaxis [27]. The difference in results could
be explained by the fact that our protocol recommended
thromboprophylaxis after procedures on the spine. A
low rate of VTE was also found in a recent study when
mechanical prophylaxis was used [28].
Low VTE incidence in procedures performed without
routine thromboprophylaxis was found after knee arth-
roscopy (0.5%; 95% CI: 0.3-0.7), foot surgery (0.7%; 95%
CI: 0.4-1.1) and upper extremity surgery (0.2%; 95% CI:
0.1-0.3) and therefore routine thromboprophylaxis does
not seem justified in these procedures. These results are
comparable with previous reports in the topic [29-31].
The distribution of DVTs in proximal and distal veins
followed the fracture type with higher rate of proximal
DVTs in proximal fractures and vice versa. This relation
was found also after hip and knee replacement, also
demonstrated in a previous study [4]. The higher rate of
proximal DVTs after hip replacement has been assigned
to a local injury to the femoral vein occurring when the
leg is flexed and rotated during the surgery [32-34], it is
likely that local vascular injuries also play an important
role in the formation of DVT after lower limb fracture.
The rate of DVTs diagnosed after hospital discharge was
92% after hip replacement and 55% after knee replace-
ment (for VTEs corresponding rates were 90% and 57%,
respectively). Similar differences have been reported previ-
ously [3,29]. Reasonable mechanisms for late-occurring
VTE have been related to prolonged activation of the co-
agulation system [35,36]. A prolonged reduction in ven-
ous outflow has also been described, persisting for
6 weeks after hip replacement [37,38] but normalizing
during the first week after knee replacement [39], differ-
ences that possibly could be explained by the use of
tourniquet and the associated venous stasis and more
extensive soft-tissue damage in knee replacement
surgery, leading to extensive local release of tissue factor
[12]. These findings support the present guidelinesrecommending prolonged prophylaxis, especially im-
portant after hip replacement surgery [1].
The results with 513 VTEs diagnosed over a 10 year
period correspond in average to one event per week on
a department with more than 30 orthopedic surgeons.
This indicates that the diagnosis of a postoperative VTE
is an uncommon finding for a single orthopedic surgeon.
Since most of the VTEs were diagnosed after discharge
from hospital, often by other physicians than orthopedic
surgeons, a systematic feedback or registration of post-
operative VTE could be important for complication
awareness and quality control after surgery. With this
study, we demonstrate that registration of adverse events
can be performed with high validity when using dedi-
cated personnel. A number of VTEs remained however
unregistered, the reason for this could not be identified
but these cases where consequently included retrospect-
ively in the analysis. Another possible source of under-
estimation of the true rate of VTE could be poor clinical
awareness of thromboembolic complications as well as
difficulties in distinguishing VTE symptoms from nor-
mal postoperative findings. In addition, many patients
with a fatal PE remained most certainly undiagnosed in
our study due to a low autopsy rate and since the course
of this condition is often very rapid and results in sud-
den death before resuscitation [40,41]. The extremely
high rate of fatal PE (20 out of 45) seen in the autopsies
could possibly be explained by selection bias but the re-
sults still indicates that fatal PE remains a serious threat
after orthopaedic surgery. Based on the validity control,
we believe that the overall data quality in our study is
highly valid. Furthermore, the annual VTE and mortality
incidence has shown a consistency over the ten year
study period (data not shown) not affected by other pos-
sible changes in routines at the department over time.
The relatively short postoperative follow-up period of
6 weeks is a limitation of our study. It is known that the
risk for VTE after major orthopaedic surgery remains
higher than normal for 2–3 months [3-5]. The majority
of thromboembolic events occur however, during the
first post-surgical month [4]. This is confirmed in our
retrospective analysis with only 10% late occurring VTEs
in postoperative week 7 to 12, findings that also are
presented. We therefore believe that our results provide
the reader valuable information regarding postoperative
VTE after orthopaedic surgery. Strengths of the study
include a remarkable follow-up rate of a large number of
consecutive patients in a prospective study including
VTEs also diagnosed elsewhere.
Conclusions
Although the overall incidence of VTE after orthopaedic
surgery was low our study highlights surgical procedures
after which the risk for VTE remains high and improved
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present after hospital discharge special attention is needed
to prevent and diagnose these late thromboembolic events.
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